Search results for "Steatosi"

showing 10 items of 261 documents

Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

2013

Background and aims: Lower 25-Hydroxyvitamin D (25[OH]D) serum lev- els have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC). In addition, a recent genome-wide study identified genetic variants (rs12785878, near dehydrocholesterol reduc- tase, DHCR7; rs10741657, near CYP2R1; and rs7041, near vitamin D binding protein, GC) affecting 25(OH)D serum levels in healthy populations. We aimed to assess the association between vitamin D serum levels and its genetic determinants, with the severity of liver fibrosis. Material and methods: Two hundred sixty patients with biopsy-proven G1CHC were consecutively evaluated. The 25(OH)D serum levels wer…

VitaminAdultLiver CirrhosisMaleSerummedicine.medical_specialtyOxidoreductases Acting on CH-CH Group DonorsGenotypeHepatitis C virusSingle-nucleotide polymorphismHepacivirusBiologyReductasemedicine.disease_causeGastroenterologychemistry.chemical_compoundFibrosisVirologyInternal medicineGenotypemedicineVitamin D and neurologyHumansVitamin DCytochrome P450 Family 2Chromatography High Pressure LiquidHCV VITAMIN D DHCR7Settore MED/12 - GastroenterologiaPolymorphism GeneticHepatologyVitamin D-Binding ProteinHepatitis C ChronicMiddle Agedmedicine.diseaseInfectious DiseaseschemistryImmunologyCholestanetriol 26-MonooxygenaseFemaleSteatosisJournal of viral hepatitis
researchProduct

Role of LECT2 in non alcoholic fatty liver disease

2020

The liver is the privileged site of metabolic regulations that must be tightly coordinated to prevent metabolic imbalance to preserve homeostasis. Alteration of these processes can promote steatosis, an essential feature of Non-Alcoholic Fatty Liver Diseases (NAFLD), representing the new global epidemic threat. During this thesis work, we demonstrated that LECT2, a liver secreted factor, is increased in both Human and mice harboring fatty liver. In a physiological context, we demonstrated that LECT2 controls liver lipogenesis through the LXR signalling pathway. At the molecular level, the absence of LECT2 induces a specific accumulation of 25-OHC oxysterol which leads to a significant incre…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySteatosisLect2LiverStéatoseLipogenesisLipogenèseLxrFoie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Prebiotic Xylo-oligosaccharides Targeting Faecalibacterium prausnitzii Prevent High Fat Diet-induced Hepatic Steatosis in Rats

2020

Understanding the importance of gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat associated with low abundance of Faecalibacterium prausnitzii in humans and further, administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed to target F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD) or low (LFD) fat-diet for 12-weeks in Wistar rats (n=10/group). XOS increased F. prausnitzii growth having only minor impact on the GM composition. When supp…

biologyChemistryPrebioticmedicine.medical_treatmentdigestive oral and skin physiologyFatty livergastroenterologynutritional and metabolic diseasesfood and beveragesFaecalibacterium prausnitziiHigh fat dietMetabolismGut floraMitochondrionmedicine.diseasebiology.organism_classificationdigestive system3. Good healthmedicineFood scienceSteatosis
researchProduct

Applicazione dei mezzi di contrasto ecografici nelle lesioni focali del fegato steatosico, nelle lesioni epatiche rare e nelle pseudolesioni del fega…

2007

Nonostante i continui progressi tecnologici, l’ecografia convenzionale in scala di grigi non presenta elevata specificita nella caratterizzazione delle lesioni focali epatiche [1]. Inoltre, nella pratica clinica, il non infrequente riscontro di alterazioni diffuse del parenchima epatico, come la steatosi, puo rendere ancora piu difficoltosa una corretta diagnosi [2]. In particolare l’infiltrazione adiposa del fegato,dovuta all’accumulo di trigliceridi sotto forma di vacuoli di differenti dimensioni all’interno degli epatociti, la cui incidenza, secondo alcuni studi autoptici, varia dal 6 all’11%, e responsabile di un’ alterazione diffusa dell’ecogenicita del parenchima epatico che assume un…

ecografia con mezzo di contrastolesioni focalisteatosi epatica
researchProduct

Affidabilità del bright liver nella steatosi epatica in soggetti con ipertransaminasemia criptogenetica e con epatopatia da virus C

2008

ecografiasteatosi epatica ipertransaminasemia affidabilità
researchProduct

Caratterizzazione delle lesioni focali epatiche ipoecogene in pazienti con fegato steatosico: “performance” e livello di confidenza diagnostica dell’…

2007

fegato steatosicoecografia con mezzo di contrastolesioni focali epatiche
researchProduct

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

2023

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease worldwide. Curcumin and andrographolide are famous for improving hepatic functions, being able to reverse oxidative stress and release pro-inflammatory cytokines, and they are implicated in hepatic stellate cell activation and in liver fibrosis development. Thus, we tested curcumin and andrographolide separately and in combination to determine their effect on triglyceride accumulation and ROS production, identifying the differential expression of genes involved in fatty liver and oxidative stress development. In vitro steatosis was induced in HepG2 cells and the protective effect of curcumin, andrographolide, and…

lipid dropletsOrganic ChemistryandrographolidePharmaceutical ScienceGKROSAnalytical Chemistryliver steatosisSettore BIO/13 - Biologia ApplicataChemistry (miscellaneous)NAFLDDrug DiscoveryPPARGC1Aliver steatosis.Molecular MedicineFABP1curcuminPhysical and Theoretical ChemistryMolecules
researchProduct

Aknu steatozes saistība ar hroniska pankreatīta gaitu

2019

Ievads. Hronisks pankreatīts ir hroniska iekaisīga aizkuņģa dziedzera slimība, kas var novest līdz eksokrīnai un endokrīnai mazspējai. Literatūrā ir atrodami maz dati par aknu steatozes prevalenci hroniska pankreatīta pacientu vidū, lai gan abām šīm slimībām ir kopīgi etioloģiskie faktori. Darba mērķis. Analizēt aknu steatozes prevalenci HP slimniekiem un novērtēt aknu steatozes asociāciju ar HP smaguma pakāpi un komplikācijām. Metodes un materiāli. Pētījums bija retrospektīvs šķērsgriezuma pētījums. Tajā tika iekļauti pacienti no PSKUS Gastroenteroloģijas, hepatoloģijas un uztura terapijas centra, laika periodā no 2016. gada līdz 2019. gadam. Tika apkopoti tādi klīniskie parametri kā demog…

liver steatosischronic pancreatitisexocrine insufficiencychronic pain syndromeMedicīna
researchProduct

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD

2021

Background and aim: Coffee intake exerts protective effects against non-alcoholic fatty liver disease (NAFLD), although without fully cleared mechanisms. In this study we aimed to assess whether coffee consumption may influence the expression of long non-coding RNAs (lncRNAs) in the liver. Methods: C57BL/6J mice were fed a 12-week standard diet (SD), high-fat diet (HFD) or HFD plus decaffeinated coffee solution (HFD + coffee). Expression of specific lncRNAs involved in NAFLD was analyzed by real-time PCR. For the most differentially expressed lncRNAs, the analysis was also extended to their mRNA targets. Results: Decaffeinated coffee intake reduced body weight gain, prevented NAFLD, lowered…

lncRNA.Liver CirrhosisMalemedicine.medical_specialtyGm16551; H19; NAFLD; coffee; lncRNA; Animals; Coffee; Disease Models Animal; Fatty Liver; Gene Expression; Liver; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Non-alcoholic Fatty Liver Disease; RNA Long NoncodingCoenzyme ACircadian clockcoffeeGene ExpressionBiologyInbred C57BLArticlechemistry.chemical_compoundMicelncRNADownregulation and upregulationFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineAnimalsTX341-641Messenger RNANutrition and DieteticsH19Nutrition. Foods and food supplyAnimalGm16551Fatty liverNAFLD; coffee; lncRNA; Gm16551; H19nutritional and metabolic diseasesmedicine.diseaseMice Inbred C57BLFatty LiverDisease Models AnimalEndocrinologychemistryLiverLipogenesisDisease ModelsRNARNA Long NoncodingLong NoncodingSteatosisFood Science
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct